Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

U.K. partners to accelerate gene therapy development for dementia

CGT Catapult, UK DRI to work with academic centers to identify assets

June 20, 2022 11:56 PM UTC

A new partnership in the U.K. aims to drive the development of gene therapies for dementia-related diseases.

The Cell and Gene Therapy Catapult and the UK Dementia Research Institute partnered Monday to identify AAV-based gene therapies for dementia in collaboration with U.K. academic centers of excellence. After identifying programs, the partners will create development plans for each project with the potential for further early-stage research ahead of any investment for future development. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article